ERBB2 and breast cancer: Guided spectral imaging analysis of a murine model of hormone receptor-negative, HER2-negative (triple-negative) breast cancer showed fluorescent localization in the tumor at 2 and 24 h following intra-tumoral injection of FND, with less fluorescence noted in the spleen at both time points.